Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Biostem Technologies Inc

Healthcare US BSEM

4.14USD
-0.03(0.72%)

Last update at 2026-06-03T19:26:00Z

Day Range

4.064.19
LowHigh

52 Week Range

3.0915.50
LowHigh

Fundamentals

  • Previous Close 4.17
  • Market Cap78.07M
  • Volume10799
  • P/E Ratio5.27
  • Dividend Yield-%
  • EBITDA-0.45935M
  • Revenue TTM47.48M
  • Revenue Per Share TTM2.84
  • Gross Profit TTM 44.44M
  • Diluted EPS TTM0.88

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax 30.61M -8.48298M -7.11371M -1.41178M -2.36923M
Minority interest - 0.00000M 0.04M -0.03360M -0.02000M
Net income 31.88M -8.48298M -7.07486M -1.44538M -2.38923M
Selling general administrative 254.75M 22.63M 10.43M 4.19M 3.09M
Selling and marketing expenses - - - - -
Gross profit 288.08M 15.42M 5.99M 2.87M 1.25M
Reconciled depreciation 0.29M 0.23M 0.24M 0.28M 0.24M
Ebit - - -4.68155M -1.60570M -
Ebitda - - -6.40214M -0.60199M -1.59486M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 31.20M -7.77897M -4.68155M -1.60571M -1.84226M
Other operating expenses - - - - -
Interest expense 0.59M 0.70M 0.47M 0.53M 0.53M
Tax provision -1.27090M 0.00000M - - 0.00000M
Interest income - - - - 0.00393M
Net interest income -0.58722M -0.70033M -0.46815M -0.52588M -0.52697M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 301.83M 16.69M 6.88M 4.34M 2.52M
Total operating expenses 270.63M 24.46M 11.56M 5.95M 4.36M
Cost of revenue 13.75M 1.26M 0.88M 1.47M 1.27M
Total other income expense net - -0.00369M -1.96401M 0.72M -
Discontinued operations - - - - -
Net income from continuing ops 31.88M -8.48298M -7.11371M -1.41178M -2.36923M
Net income applicable to common shares - - -7.07486M -1.44538M -
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 140.38M 14.56M 3.47M 2.67M 2.67M
Intangible assets 0.22M 0.35M 0.36M 0.21M -
Earning assets - - - - -
Other current assets 2.87M 0.33M 0.28M 0.04M -0.00000M
Total liab 99.50M 15.54M 7.42M 8.47M 8.30M
Total stockholder equity 40.88M -0.98367M -4.07640M -5.95940M -5.80220M
Deferred long term liab - - - - -
Other current liab 0.71M 0.29M 0.16M 0.34M 0.19M
Common stock - - 0.01M 0.00974M -
Capital stock 0.02M 0.02M 0.01M 0.00974M 3.68M
Retained earnings -13.73980M -45.00392M -37.02305M -29.94828M -28.20047M
Other liab - - 0.05M 0.12M -
Good will 0.24M 0.24M 0.24M 0.24M 0.47M
Other assets - - -0.00000M - -
Cash 22.83M 0.24M 0.77M 0.34M 0.10M
Cash and equivalents - - - - -
Total current liabilities 99.17M 15.26M 6.33M 6.54M 6.80M
Current deferred revenue - - - - -
Net debt - 4.47M 4.30M 4.46M 5.21M
Short term debt - - - - -
Short long term debt 3.96M 4.45M 4.04M 3.00M 3.99M
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - - 1.37M 1.28M -
Total current assets 133.76M 12.60M 1.49M 0.94M 0.85M
Long term investments - - - - -
Net tangible assets - - -4.68360M -6.41408M -
Short term investments - - - - -
Net receivables 104.98M 11.37M 0.04M 0.30M 0.01M
Long term debt 0.15M 0.27M 1.03M 1.80M 1.32M
Inventory 1.82M 0.66M 0.40M 0.26M 0.57M
Accounts payable 5.29M 1.03M 0.57M 0.65M 0.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 6.61M 1.96M 1.98M 1.73M 1.82M
Capital lease obligations 0.29M 0.01M 0.02M 0.03M 0.31M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -1.67657M -0.21033M -0.46948M -0.00785M 0.00000M
Change to liabilities - - -0.07714M -0.01949M -
Total cashflows from investing activities - - -0.46948M -0.00785M -
Net borrowings -0.84940M 0.80M 0.52M 0.23M -
Total cash from financing activities -0.20678M 3.18M 0.57M 0.36M 0.54M
Change to operating activities - - -0.04303M 0.61M -
Net income 31.88M -7.86278M -7.07486M -1.44538M -2.38923M
Change in cash 22.59M -0.53273M 0.43M 0.24M -0.04004M
Begin period cash flow 0.24M 0.77M 0.34M 0.10M 0.14M
End period cash flow 22.83M 0.24M 0.77M 0.34M 0.10M
Total cash from operating activities 24.48M -3.49896M -1.63694M -0.10944M -0.58157M
Issuance of capital stock - 2.38M 0.05M 0.12M -
Depreciation 0.29M 0.23M 0.24M 0.28M 0.24M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -1.16532M -0.26345M -0.13518M 0.21M -0.00599M
Change to account receivables -93.78336M -11.33452M 0.26M -0.28825M 0.07M
Sale purchase of stock -0.00000M 0.00000M - - -
Other cashflows from financing activities - - - - -
Change to netincome - - 5.19M 0.54M -
Capital expenditures 0.43M 0.21M 0.24M 0.04M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -12.01088M -3.08161M 0.00758M 0.52M 0.92M
Stock based compensation 6.66M 5.76M 4.90M 0.40M -
Other non cash items 0.46M 1.46M 0.32M 0.79M 0.38M
Free cash flow 24.05M -3.70929M -2.10643M -0.15229M -0.58157M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BSEM
Biostem Technologies Inc		 -0.03 0.72% 4.14 5.27 13.62 1.64 1.52 0.18 3.34
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.38 0.89% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Biostem Technologies Inc

4901 Northwest 17th Way, Fort Lauderdale, FL, United States, 33309

Key Executives

Name Title Year Born
Mr. Jason Matuszewski Interim Chairman, CEO, Pres & Sec. NA
Mr. Michael Fortunato CPA Chief Financial Officer NA
Mr. Andrew Vanvurst COO & Director NA
Dr. David M. Woynarowski Chief Medical Officer NA
Mr. Larry Jones Chief Revenue Officer NA
Dr. Irmgard Huber M.D. International Medical Advisor & Interim Chief Medical Officer NA
Mr. Jason Matuszewski CEO, President, Director & Secretary NA
Mr. Shawn F. McCarrey Chief Commercial Officer 1958
Mr. Jason V. Matuszewski CEO, President, Director & Secretary 1986
Mr. Michael A. Fortunato CPA Chief Financial Officer 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.